Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Shinichiro Izawa"'
Autor:
Yuya Yoshimoto, Yoshiyuki Suzuki, Kousaku Mimura, Ken Ando, Takahiro Oike, Hiro Sato, Noriyuki Okonogi, Takanori Maruyama, Shinichiro Izawa, Shin-ei Noda, Hideki Fujii, Koji Kono, Takashi Nakano
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e92572 (2014)
PURPOSE: There is growing evidence that tumor-specific immune responses play an important role in anti-cancer therapy, including radiotherapy. Using mouse tumor models we demonstrate that irradiation-induced anti-tumor immunity is essential for the t
Externí odkaz:
https://doaj.org/article/0081fc15262c4483a205fd2687fa2df4
Autor:
Rolf Kiessling, Kousaku Mimura, Ryohei Katoh, Shugo Shiba, Shingo Inoue, Takanori Maruyama, Tomonori Kawasaki, Yoshihiko Kawaguchi, Masayuki Inoue, Shinichiro Izawa, Aniruddha Choudhury, Mitsuaki Watanabe, Hideki Fujii, Ayako Inoue, Koji Kono, Kensuke Shiraishi
Publikováno v:
Oncoimmunology
HER2 is a promising target for immunotherapeutic interventions with T cell-based approaches since it is amplified and overexpressed in 20-30% of breast cancers. However, several previous studies including ours showed that HER2-overexpressing tumors m
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 71:3166-3170
稀な疾患である多発性大腸リンパ管腫が原因となった腸重積症の1例を経験したので報告する.症例は17歳,女性.腹痛を主訴に来院.腹部超音波検査および腹部造影CT検査で上行結腸に
Autor:
Hideki Fujii, Barbara Seliger, Rolf Kiessling, Anja Mueller, Jimmy Bok Yan So, Shinichiro Izawa, Kensuke Shiraishi, Wei Peng Yong, Koji Kono, Ley-Fang Kua, Kousaku Mimura
Downregulation of HLA class I expression may contribute to a poor prognosis in cancer patients. There is limited information about epigenetic and oncogenic regulation of HLA class I, and multiple mechanisms may be involved. In the current study, we e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c48ba931240dcfd3a888bf8f6ecabd
https://europepmc.org/articles/PMC3856928/
https://europepmc.org/articles/PMC3856928/
Autor:
Mitsuaki Watanabe, Masayuki Inoue, Takanori Maruyama, Shugo Shiba, Koji Kono, Ayako Inoue, Kensuke Shiraishi, Hideki Fujii, Yoshihiko Kawaguchi, Shinichiro Izawa, Kousaku Mimura
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 16(4)
Trastuzumab has been recently approved for clinical use to treat HER2-expressing advanced gastric cancer, and anti-HER2-targeting therapy has become a promising option for gastric cancer. Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR a
Autor:
Kousaku, Mimura, Shinichiro, Izawa, Shugo, Siba, Takanori, Maruyama, Mitsuaki, Watanabe, Yoshihiko, Kawaguchi, Hideki, Fuji, Koji, Kono
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 38(12)
Although esophageal squamous cell carcinoma (ESCC) patients have recently been treated with the combined modality therapy, the prognosis remains poor. For the development of new strategies in ESCC, we examined possibilities of the immune -based thera
Autor:
Takanori, Maruyama, Kousaku, Mimura, Shinichiro, Izawa, Ayako, Inoue, Shugo, Shiba, Mitsuaki, Watanabe, Yoshihiko, Kawaguchi, Masayuki, Inoue, Hisashi, Nogata, Shingo, Inoue, Hideki, Fujii, Koji, Kono
Publikováno v:
Anticancer research. 31(9)
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purpo
Autor:
Hideki Fujii, Tetsuo Kono, Kousaku Mimura, Koji Kono, Yoshihiko Kawaguchi, Shinichiro Izawa, Rolf Kiessling, Yoshiki Mizukami, Mitsuaki Watanabe, Masayuki Inoue, Aniruddha Choudhury, Takanori Maruyama, Shugo Shiba
Publikováno v:
International journal of cancer. 129(10)
Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains. EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs). To explore the potential utility of Lapatinib for therapy of ESCC
Autor:
Takanori Maruyama, Shugo Shiba, Mitsuaki Watanabe, Koji Kono, Yoshihiko Kawaguchi, Shinichiro Izawa, Kousaku Mimura, Hideki Fujii
Publikováno v:
Nutrition (Burbank, Los Angeles County, Calif.). 27(2)
Objective Although randomized clinical trials have shown that immunonutrition results in the improvement of postoperative complications, the detailed mechanisms of its immunomodulation are still unclear. In the present study, we investigated if such
Autor:
Kousaku Mimura, Shin-ei Noda, Noriyuki Okonogi, Takahiro Oike, Takanori Maruyama, Ken Ando, Hiro Sato, Yoshiyuki Suzuki, Koji Kono, Takashi Nakano, Yuya Yoshimoto, Hideki Fujii, Shinichiro Izawa
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 3, p e92572 (2014)
PLoS ONE, Vol 9, Iss 3, p e92572 (2014)
PURPOSE: There is growing evidence that tumor-specific immune responses play an important role in anti-cancer therapy, including radiotherapy. Using mouse tumor models we demonstrate that irradiation-induced anti-tumor immunity is essential for the t